Badr Eldin, H., Helmy, W. (2007). Expression of Her-2/neu in endometrial carcinoma and its relation with clinicopathological variables. The Egyptian Journal of Hospital Medicine, 28(1), 418-428. doi: 10.21608/ejhm.2007.17671
Hanaa O Badr Eldin; Wafaa H A Helmy. "Expression of Her-2/neu in endometrial carcinoma and its relation with clinicopathological variables". The Egyptian Journal of Hospital Medicine, 28, 1, 2007, 418-428. doi: 10.21608/ejhm.2007.17671
Badr Eldin, H., Helmy, W. (2007). 'Expression of Her-2/neu in endometrial carcinoma and its relation with clinicopathological variables', The Egyptian Journal of Hospital Medicine, 28(1), pp. 418-428. doi: 10.21608/ejhm.2007.17671
Badr Eldin, H., Helmy, W. Expression of Her-2/neu in endometrial carcinoma and its relation with clinicopathological variables. The Egyptian Journal of Hospital Medicine, 2007; 28(1): 418-428. doi: 10.21608/ejhm.2007.17671
Expression of Her-2/neu in endometrial carcinoma and its relation with clinicopathological variables
1Departments of Obstetrics Faculty of medicine, Al Azhar University.
2Gynecology and Pathology Faculty of medicine, Al Azhar University.
Abstract
Objective and background: Her-2/neu tyrosine kinase has been implicated in the development and progression of several human cancers and is target for therapeutic intervention. Smaller studies suggest that Her-2/neu may be involved in the tumerogenesis of endometrial adenocarcinoma. The aim of this study was to evaluate Her-2/neu expression in endometrial carcinoma (EC) and its correlation with clinicopathological features in order to define the potential prognostic value of Her-2/neu overexpression in EC. Patients and methods: Nineteen patients with stage I-IV EC were included in this study. Demographic, clinical and pathologic information was obtained and recorded. Her-2/neu expression was evaluated by immunohistochemistry (IHC) on paraffin embedded tissue sections with Her-2/neu antibody. Overexpression was defined as complete membrane staining in greater than 10% of cells. Results: The positive rate of Her-2/neu in EC was 42.1%. Her-2/neu was associated with surgical stage (p<0.01), lymph node involvement (p<0.05), lymph vascular space invasion (p <0.05) and depth of myometrial invasion (p <0.01) but not associated with histological grade or the age of the patients (p >0.05). Conclusion: Our study provides evidence of Her-2/neu overexpression in a considerable proportion of the patients with uterine adenocarcinoma, thus suggesting the opportunity for the possible use of anti-Her-2/neu therapy in this malignancy by selective inhibition of Her-2/neu. The use of Herceptin, a monoclonal antibody directed against Her-2/neu, for therapy of patients harboring Her-2/neu positive EC may be beneficial. Her-2/neu overexpression is related to most of the prognostic variables of EC and may be incorporated into the criteria for determination of tumor aggressiveness as a prognostic marker.